ATOS Skyrockets, BPMX Gets "Going Concern" Warning, Respite For KPTI

Today’s Daily Dose brings you news about the positive progress of Atossa Genetics’ Oral Endoxifen as a post-mastectomy treatment for breast cancer; BioLife Solutions’ stellar fourth-quarter financial results; BioPharmX Corp’s anticipated milestones in 2019; revised FDA decision date of Karyopharm’s Selinexor; and clinical trial catalysts of SCYNEXIS. Read on… Shares of Atossa Genetics Inc. (ATOS) jumped more than 350% on […]

Read more

NantKwest Gets A Shot In The Arm, CPRX Awaits FDA Word, FOMX Meets Phase 3 Goals

Today’s Daily Dose brings you news about the near-term catalysts of Catalyst Pharma; progress in Entasis’ gonorrhea study; positive results of Foamix Pharma’s phase III papulopustular rosacea studies; Lannett’s revised revenue outlook; NantKwest’s cancer vaccine trial results; Nu Skin Enterprises’ Q3 financial results and Rennova Health’s reverse stock split. Read on… Catalyst Pharmaceuticals Inc. (CPRX) has an important catalyst to […]

Read more